NEJM: New breakthroughs in clinical trials of CAR-T therapy
Release date: 2017-12-12 Recently, researchers from the Loyola University Medical Center conducted a groundbreaking clinical trial to kill cancer cells by modifying the patient's immune system. The study was published in the latest issue of the New England Journal of Medicine. The co-author is Patrick Stiff, director of the Cardinal Bernardin Cancer Center at Loyola University. The therapy used in this clinical trial is called "CAR-T", the provider of the therapy is Kite Pharmaceuticals, and Novartis and Juno Therapeutics are also developing CAR-T therapies for cancer. (Image taken from ) Dr. Stiff said that next year they will be doing CAR-T treatment for cancer patients with other treatments that are not effective. However, although this therapy will provide new options for patients who have poor effects on conventional therapy, it will also have serious negative effects and higher treatment costs. Dr. Stiff said that Loyola University would give patients similar clarifications about the strengths and weaknesses of the therapy and help them make decisions about treatment. Based on the results of this study, the FDA approved a CAR-T therapy called Yescarta. The study included 111 patients from different cancer centers who had specific types of B-cell lymphoma and relapsed after undergoing other treatments. In this regard, the researchers collected T cells from patients and then genetically modified them under laboratory conditions to target killing lymphoma cells. Finally, these cells were returned to the patient after amplification. For more than a year after treatment, 42 patients were fully recovered. “The results are impressive, after all, these patients are not sensitive to other treatments,†Dr. Stiff said. Of course, 95% of patients have at least one negative symptom, 30% of them have severe cytokine recurrence syndrome (CRS), which leads to high fever or flu-like symptoms, and 28% of patients have neurological disorders. Wait. However, the above symptoms will gradually decrease over time, which may be due to the increased treatment experience of doctors. Dr. Stiff believes that Loyola University's clinical experience in this area, as well as basic experience in the treatment of lymphoma patients, will help them provide safer and more effective CAR-T treatment options for patients. Information source: Landmark CAR-T cancer study published Source: Bio Valley Hongxing Factory Chemical Protective Boots,Pvc Rain Boot,Chemical Resistant Rain Boots,Industry Rain Shoes Waterproof Dongying Hong Xing Labor Protection Products Co.,Ltd. , https://www.hongxinglabor.com
Dongying Hongxing is located at Dongying City, Shandong Province China since 1995.
We have 30 categories of products, including Covid-19 products, frock, protection shoes, safety belt, Special gloves.
Our main customer in China is Sinopec, Petro China, Energy company, steel company and Tabacco Company in other countires. Our factory have 500workers and 22 technical employees and invest thirty eight million dollars .
FAQ
1. What are your main products ?- Safety shoes
- Protective helmet
- Work clothes
- Safety cloves
- Protective equipment and masks
2. Can you offer OEM ?
Our company accep OEM service , if you need, please inform us of your specific requirements
3. What's your mode of transportation ?
By sea, By air, By train, By truck, as your request. We also do a good job to deliver goods to your destination.
4. What's your payment terms ?
T/T, L/C, Paypal..... If you need to pay via other ways, please negotiate with us.
5. Can you offer sample ?
Yes, we can offer samples to help you check type and quality.
6. Are you manufacturer or trader ?
We have own factory in Donying city, Shandong province, welcom to visit our factory !